Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CANDESARTAN | 16MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166595 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2021-05-14 | 2021-07-30 | 139406 |
| APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2021-10-22 | 2021-10-22 | 147815 |
| APO-CANDESARTAN | Resolved | 2020-03-09 | 2020-05-04 | 108228 | ||
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2020-04-13 | 2020-10-19 | 111895 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2020-05-13 | 2020-09-21 | 114928 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2021-06-14 | 118761 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2020-09-21 | 118763 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18517 |
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18520 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2017-03-11 | 2017-06-27 | 639 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-03-12 | 2018-09-09 | 706 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2017-03-20 | 2020-02-25 | 3516 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-09-20 | 2025-03-07 | 238233 |
| APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2025-01-17 | 239355 |
| APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2024-12-06 | 239358 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-12-12 | 2025-03-07 | 245502 |
| APO-CANDESARTAN TABLETS | 8MG | TABLET | Resolved | 2025-01-30 | 2025-03-14 | 249077 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2025-03-20 | 2025-04-11 | 253078 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Resolved | 2017-09-07 | 2018-02-26 | 21199 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |